THE WOODLANDS, Texas, July 13, 2004 (PRIMEZONE) -- Power3 Medical Products, Inc. (OTCBB:PWRM) announces today the completion of a stage of clinical validation on its neurodegenerative disease blood test, developed by the Company in collaboration with Stan Appel, M.D., Chairman of the Department of Neurology at Baylor College of Medicine and one of the most recognized leaders in neuromuscular and neurodegenerative disease. The completed study, which involved analyzing additional serum samples from 104 patients with Lou Gehrig's (ALS), Parkinson's, Alzheimer's, and other neurological diseases, concurs with the Company's previous positive results, obtained with 79 patients and healthy individuals as a proof of concept.

During this phase of the collaboration between the research team of Power3 Medical under Dr. Ira L. Goldknopf, Chief Scientific Officer, and the team at Baylor, 183 neurodegenerative disease patients' and normal individuals' samples were analyzed, using the Company's patent-pending proteomic methods, to develop the ability to selectively diagnose in the blood serum, the neurodegenerative diseases. The test was able to discriminate between normal individuals and patients with neurodegenerative diseases at a level of 86-99%. Furthermore, when evaluated on a mixed pool of blinded sera from the patients, the preliminary results indicated an accurate differential diagnosis of ALS, Alzheimer's and Parkinson's diseases, at a level of 60-70%.

According to Dr. Ira Goldknopf, "With this test, which involves monitoring the concentration of a panel of proteins in the blood, we are able to identify unique biomarkers whose profiles appear to distinguish patients with Lou Gehrig's (ALS), Alzheimer's, and Parkinson's diseases from each other as well as from the normal individuals and patients with other neurological disorders. To our gratification, this test has exceeded our expectations and these results propel us to continue clinical validation."

Dr. Stan Appel, commented, "These protein biomarkers identified by Power3 represent a promise for early detection and identification of ALS, Alzheimer's, Parkinson's and other neurological diseases. A main problem to date is that there are no diagnostic tests or biomarkers for the early diagnosis, prognosis, and guidelines for therapy for neurodegenerative diseases. We are pleased with the progress that has been made. These biomarkers have the potential to offer unique insights into the pathogenesis of neurodegenerative disease and provide great promise to improve the clinical outcomes of our patients."